𝛼SK or SearchIPO Databook: PANACRO (Hangzhou) Pharmaceutical Consulting (HK) - Aug 2026
102 Views22 Aug 2026 10:16
SUMMARY
- Panacro (Hangzhou) Pharmaceutical Consulting Co., Ltd. is a clinical CRO based in Hangzhou, China, advancing clinical research through digital transformation. It provides clinical trial technical services to accelerate drug development.
- Proprietary digital infrastructure integrates CTMS, eTMF, and CTFS across the full project lifecycle. The company reported a gross profit margin of 38.9% in 2025.
- Net cash generated from operating activities was RMB46,583 thousand for the six months ended June 30, 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- IPO Databook: PANACRO (Hangzhou) Pharmaceutical Consulting (HK) - Aug 202622 Aug 2026
x